journal article·2024-09-04

Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade

Lei Feng, Bin Luo, Bei Li, Maling Gou, Yuting Luo, Geng Liu, Xiwen Ye, Jianrong Xu, Yaotian Fan, Zhen You

ACS Applied Materials & Interfaces· Volume 16· Issue 35
Publisher page

Abstract

Immune checkpoint blockade (ICB) therapy, while showing promise in various cancers, exhibits limited effectiveness in hepatic carcinoma due to the tumor's immunosuppressive microenvironment (TME) and challenges associated with immune cell infiltration. Efforts to transform the "cold" TME into an "inflamed" state, notably through chemo-immunotherapy, have sparked interest due to their potential to induce immunogenic cell death and augment the infiltration of cytotoxic T lymphocytes (CTLs). Nonetheless, the efficacy of chemo-immunotherapy is often compromised by suboptimal pharmacokinetics, poor tumor accumulation, and off-target toxicity. Herein, in response, we introduce an innovative, milder thermal therapeutic approach leveraging gold nano frameworks with mesopores for the targeted delivery of the immunostimulant imiquimod and NIR-II photothermal therapy. This strategy employs targeted molecule modifications to ensure precise tumor targeting, guided by photoacoustic imaging. Subsequent to mild thermal treatment, there is a release of immunogenic proteins (CRT and HSP90), enhancing tumor immunogenicity. Assisted by imiquimod, substantial CTL infiltration occurs, accompanied by pro-inflammatory factor release (TNF-α, IL-6), transforming M2 macrophages into the M1 phenotype. Ultimately, the proposed strategy combines PD-L1/PD-1 blockade, imiquimod and mild thermal treatment to synergistically enhance tumor immunogenicity, remodel the TME, and restrain hepatic carcinoma, making strides in ICB synergistic immune-thermal therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Biliary Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Research Center for Biliary Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Department of Gastrointestinal Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Funding

National Natural Science Foundation of China

References (28)

Show source-provided references
1. 10.1038/s41573-021-00155-y10.1038/s41573-021-00155-y ↗
2. 10.1016/j.cell.2021.09.02010.1016/j.cell.2021.09.020 ↗
3. 10.1016/j.ccell.2023.07.01110.1016/j.ccell.2023.07.011 ↗
4. 10.1126/scitranslmed.abj127010.1126/scitranslmed.abj1270 ↗
5. 10.1016/j.apsb.2021.05.01610.1016/j.apsb.2021.05.016 ↗
6. 10.1016/j.apsb.2022.05.00810.1016/j.apsb.2022.05.008 ↗
7. 10.1016/j.biomaterials.2022.12164510.1016/j.biomaterials.2022.121645 ↗
8. 10.1002/adma.20210665410.1002/adma.202106654 ↗
9. 10.1016/j.med.2021.01.00510.1016/j.med.2021.01.005 ↗
10. 10.1038/s41591-023-02786-710.1038/s41591-023-02786-7 ↗
11. 10.1016/j.ajt.2024.01.00710.1016/j.ajt.2024.01.007 ↗
12. 10.1016/S1470-2045(23)00540-510.1016/S1470-2045(23)00540-5 ↗
13. 10.1016/s1470-2045(23)00469-210.1016/s1470-2045(23)00469-2 ↗
14. 10.1002/jso.2754510.1002/jso.27545 ↗
15. 10.1016/j.mtbio.2022.10048210.1016/j.mtbio.2022.100482 ↗
16. 10.1126/sciadv.aaz420410.1126/sciadv.aaz4204 ↗
17. 10.1016/j.apsb.2019.01.01810.1016/j.apsb.2019.01.018 ↗
18. 10.1021/acsami.8b0587610.1021/acsami.8b05876 ↗
19. 10.1093/annonc/mdy55110.1093/annonc/mdy551 ↗
20. 10.1016/j.annonc.2020.10.47810.1016/j.annonc.2020.10.478 ↗
21. 10.1002/advs.20200108810.1002/advs.202001088 ↗
22. 10.1039/D0CS00664E10.1039/D0CS00664E ↗
23. 10.1002/adfm.20190882510.1002/adfm.201908825 ↗
24. 10.1073/pnas.230036612010.1073/pnas.2300366120 ↗
25. 10.1016/j.cej.2023.14716110.1016/j.cej.2023.147161 ↗
26. 10.1002/adfm.20210318610.1002/adfm.202103186 ↗
27. 10.1021/acs.chemrev.3c0015910.1021/acs.chemrev.3c00159 ↗
28. 10.1021/acs.nanolett.3c0008910.1021/acs.nanolett.3c00089 ↗